Table 2.
Pattern of S100/Mammaglobin/SOX10/DOG-1 immunostaining and molecular diagnostic results from the included studies
| S. no | Study | Type of Salivary gland Tumors | Total | Immunohistochemistry | Molecular Findings | Final/Revised Diagnosis | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| S100 | SOX 10 | DOG1 | MMG | FISH | RT-PCR | NGS | |||||
| 1 | Urano M/2015 Japan | AciCC 18 | 18 | (P)17/18 | (P)3/18 | (P)3/18 | (P)13/18 |
ETV6-NTRK3 10 ND 8 |
ETV6-NTRK3 7 ND 11 |
ETV6-NTRK3 10 ND 8 |
SC 10; Aci CC 6; LGCCC 2 |
| 2 | Woo WY/2017 Australia | SC 1 | 1 | (P)1/1 | (P)1/1 | (P)0/1 | (P)1/1 | NA | NA | NA | SC 1 |
| 3 | Baghai F/2017 Iran | AciCC 7 | 10 | (SD)7/7 | (SD)7/7 | (FP)1/10 | (SD)7/7 |
ETV6 8 ND 1 NA 1 |
ETV6-NTRK3 7 ND 3 |
NA | SC 8 |
| ANOS 3 | (FP-2; SD-1) 2/3 | (SD)3/3 | (FP)2/10 | (SD)3/3 | SC HG 2 | ||||||
| 4 | Baneckova M/2018 Czech Republic | SC | 2 | (DP-1; FP-1) 2/2 | (DP)2/2 | 0/2 | (DP-1; FP-1) 2/2 | ETV6 1 | ETV6-NTRK3 ND | ETV6-NTRK3 1 (Exon 5–15) | SC 2 |
| ETV6-NTRK3 1 | ETV6-NTRK3 1 | NA | |||||||||
| 5 | Rooper LM/2018 USA | H G Aci CC 1 | 1 | (DP)1/1 | 0/1 | 0/1 | (FP)1/1 | ETV6 12p13.1 | NA |
ETV6-MET 1 (Exon 4–14) |
HG SC 1 |
| 6 | Skalova A/2018 Czech Republic | SC 10 | 10 | (P)5/6 | (P)6/10 | 0/10 | (SD)10 | ETV6-NTRK3 ND 10, ETV6-RET 10 | ETV6 7 |
ETV6-RET 10 (Exon 6–12) |
SC 10 |
| 7 | Karabachev A/2020 USA | LGAciCC | 1 | (DP)1/1 | (DP)1/1 | 0/1 | 0/1 | ETV6 12p13.2 | NA | NA | SC 1 |
| 8 | Shibata E/2020 Japan | Salivary DC | 1 | (FP)1/1 | (FP)1/1 | (FP)1/1 | (DP)1/1 | ETV6 | ETV6-NTRK3 1 | NA | SC 1 |
| 9 | Wu B/2020 Australia | AciC 1 | 1 | (DP)1/1 | (PW)1/1 | (PP)1/1 | (DP)1/1 | ETV6 | ND |
ETV6-MET 1 (Exon 4–14) |
SC 1 |
| 10 |
Li YH/2021 New Zealand |
SC 2 | 2 | (P)2/2 | (P)1/2 | 0/2 | (P)2/2 | ND | NA | NA | SC 2 |
| 11 |
Uy TC/2022 Philippiness |
SC 2 | 1 | (SD)1/1 | (SD)1/1 | 0/1 | (SD)1/1 | NA | NA | NA | SC 1 |
| 12 |
Kallarakkal TG/2022 Malaysia |
Aci CC 1 | 1 | (DP)1/1 | (DP)1/1 | (FP)1/1 | 0/1 | NA | NA | NA | AciCC HG 1 |
| 13 |
AlKaabba F/2022 USA |
SC 1 | 1 | (P)1/1 | (P)1/1 | 0/1 | (P)1/1 | NA |
mRNA fusion -5/15 (ETV6- NTRK3) |
mRNA fusion -5/15 | SC 1 |
| 14 |
Wiles AB/2022 USA |
SC | 28 | (P)23/24 | (P)3/3 | (P)0/7 | (P)17/17 | ETV6, NTRK- 33 | NA | t(12,15)(p13:q25) 1 | SC 28 |
Aci CC Acinic cell carcinoma; ANOS Adenocarcinoma not otherwise specified; DP Diffuse positive; DC Duct cyst; FP Focal positive; FISH Fluorescence insitu hybridization; HG High grade; LGCCC Low grade cribriform cystadeno carcinoma; NGS Next generation sequencing; P Positive; PP Partial positive; PW Partial weak; RT-PCR Real time polymerase chain reaction; SC Secretory carcinoma